pentagalloyl glucose
Phase 2- Indications
- Abdominal aortic aneurysm
Company intelligence / Profile preview
Nectero Medical has developed the Nectero EAST® System, an investigational single-use endovascular device that delivers pentagalloyl glucose directly into the wall of small to mid-sized abdominal aortic aneurysms. Early clinical data from their first-in-human study showed an average reduction in AAA growth rate by about 70% at 12 months compared to historical controls. The company has received both FDA Fast Track and Breakthrough Therapy designations for this technology and initiated a pivotal Phase II/III "stAAAble" trial in early 2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nectero Medical.